| Name | N-{N-[4-(Trifluoromethoxy)phenyl]carbamimidoyl}-1-pyrrolidinecarboximidamide |
|---|---|
| Synonyms |
N-{N-[4-(Trifluoromethoxy)phenyl]carbamimidoyl}-1-pyrrolidinecarboximidamide
1-Pyrrolidinecarboximidamide, N-[imino[[4-(trifluoromethoxy)phenyl]amino]methyl]- |
| Description | Lixumistat (IM156) is a novel biguanide mitochondrial protein complex 1 inhibitor of oxidative phosphorylation (OXPHOS) with anti-tumor activity. Lixumistat regulates OXPHOS to attenuate mitochondrial metabolic reprogramming and inhibit lung fibrosis. Lixumistat also suppresses B-cell activation to alleviate systemic lupus erythematosus[1][5]. |
|---|---|
| Related Catalog | |
| Target |
oxidative phosphorylation (OXPHOS)[1] |
| References |
| Density | 1.4±0.1 g/cm3 |
|---|---|
| Boiling Point | 337.2±52.0 °C at 760 mmHg |
| Molecular Formula | C13H16F3N5O |
| Molecular Weight | 315.29 |
| Flash Point | 157.8±30.7 °C |
| Exact Mass | 315.130707 |
| LogP | 0.96 |
| Vapour Pressure | 0.0±0.7 mmHg at 25°C |
| Index of Refraction | 1.578 |
| Hazard Codes | Xn |
|---|